We investigated immunohistochemically the distribution in rats of the homologous proteins gp330 and the LDL receptorrelated protein (LRP/ a2MR), and a receptor-associated protein (RAP), and the sites to which soluble exogenous RAP binds. We found gp330 in a restricted group of epithelial cells, including renal proximal tubule cells, podocytes, Type II pneumocytes, cells of the parathyroid, thyroid, epididymis, lining of the uterus, ependyma, retina, ciliary body, yolk sac, and placenta. In these cells gp330 was detected mainly at the cell surface, except for parathyroid and retinal epithelial cells, where diffuse cell staining was found. LRP/a2MR was widely distributed in interstitial cells, notably in fibroblasts and maaophages, and was also present in a selected group of epithelial or specialized cells, including hepatocytes, adrenal cortical cells, follicular cells of the ovary, cells of the choroid plexus, ciliary M y , mesangial cells, and some neurons. In certain cells, notably hepatocytes and adrenal cortical cells, LRPIa2MR was detected mainly on the surface, but in others, including maaophages, fibroblasts, and epi-* Correspondence to: Robert T. McCluskey, MD, Massachusetts General Hospital, Pathology Res., 7th Fl., 149 13th St., Charlestown, MA 02129. thelial cells of the choroid plexus and ciliary body, staining throughout the cell was seen. The only cells that clearly exp d both LRP/ a2MR and gp330 were retinal and ciliary epithelial cells. RAP was found in intracellular vesicles in all cells that expressed gp330 or LRP/a2MR. RAP was not defiitely detected on the cell surface. Binding Sites for RAP were found on the surface of those cells with surface gp330 or LRP, and also throughout the cytoplasm in cells with diffuse cellular LRP/ a2MR or gp330. Because of their different locations, we conclude that gp330 and LRP/aZMR serve distinct functions in vivo, despite similadtia in ligand-binding properties observed in vitro. Since RAP is found largely withia cells, its major physiological function may be concerned with intracellular assembly or trafficking of the receptors to which it binds. (J Histochem Cytochem 42531-542, 1994) KEY WORDS: Glycoprotein 330 (gp330); Low-density lipoprotein receptor-related protein/ a2-macroglobulin receptor (LRPlaZMR); Receptor-associated protein (RAP); Immunohistochemistry.
Introduction
The low-density lipoprotein (LDL) receptor-related protein (LRP) (1) [also known as the a2-macroglobulin receptor (a2MR)I (2,3) and gp330 are members of the LDL receptor family (4) (5) (6) . All are integral membrane calcium-binding proteins that contain cysteinerich ligand-binding (complement type) repeats, cysteine-rich repeats Supported by Grants from the National Institutes of Health DK42956, DK36807-23, R01 CA55735-02, 57T32-CA 09216-12, and GM42581. IS is a scholar of the Leukemia Society of America. of the epidermal growth factor type, a single transmembrane region, and a cytoplasmic domain that contains the amino acid sequence NPXY, which directs receptors to clathrin-coated pits (7) . LRP/a2MR is very large (4525 amino acid) receptor that mediates endocytosis of various ligands, including protease-a2MR complexes (8) (9) (10) certain proteases (11,12), and some lipoproteins (13-16).
In vivo, LRP/a2MR is thought to function mainly in clearance of ligands from the circulation by hepatocytes (17) . However, it is found in other cells, including fibroblasts and macrophages (18). Gp330 was identified by Kerjaschki and Farquhar in 1982 (19) as the major pathogenic antigen in Heymann nephritis, a rat model of membranous glomerulonephritis. Gp330 is a large glycoprotein, first estimated to have a mass of about 330 KD (19) but found in several later studies to have a higher mass (20-23). It has been proposed that gp330 is a receptor that mediates endocytosis, because it is concentrated in coated pits on certain epithelial cells (24) and because of its homology to the LDL receptor and to LRPla2MR (4) . Recently, it has been shown that gp330 can bind plasminogen (25) , extracellular matrix components (26) , and several known ligands of LRP/a2MR in vitro (16, 27, 28) .
Preparations of LRP/a2MR and gp330 invariably contain a smaller protein component, whose mass is estimated to be 39-44 KD (22, 23, 29) . This protein has been called the a2M receptorassociated protein (a2MRAP or simply RAP). In vitro, RAP inhibits the binding of ligands to LRP/a2MR and gp330 (10, 16, 22, 30, 31) .
The organ distribution of LRP/a2MR has been studied in several species by various methods, including detection of mRNA (I), uptake of labeled ligands in vivo (32) , and immunohistochemical techniques (18). The location of gp330 has been investigated mainly by immunohistochemical studies in rats, which have revealed gp330 on a restricted group of epithelial cells, including renal proximal tubule cells, glomerular podocytes, epididymal cells, and Type I1 pneumocytes (33) (34) (35) (36) . Studies in other species, i.e., humans (377, mice (38) , and dogs (39) , have revealed gp330 on renal proximal tubule cells (but not podocytes); other organs have apparently not been investigated except in the mouse (33) . The distribution of RAP has not been extensively studied, although it is known to copurify with LRP/ a2MR from liver (10) and placenta (40) and with gp330 from kidney (23, 29) . RAP has also been demonstrated by immunohistochemical methods in rat renal proximal convoluted tubule cells and podocytes (22, 23, 41) .
Knowledge of the location of LRP/a2MR, gp330, and RAP may provide insights into their functions in vivo. We performed the present immunohistochemical study to obtain further information about the distribution and interrelation of LRFVa2MR, gp330, and RAP in a wide variety of rat organs, using specific antibodies to these proteins. In addition, we used soluble RAP fusion proteins as probes to detect binding sites for RAP.
Materials and Methods
Anti-gp330 Antibadies. Two anti-gp330 monoclonal antibodies (MAb), 14C1 and 1H2, were used. The preparation and characterization of 14C1 have been previously described (20). 1H2 was obtained by immunization of mice with immunoaffinity purified gp330 and by screening with ELISA for MAb reactive with immunoaffinity-purified rat gp330 (Sy and Yahya, unpublished observations). 1H2 reacts with gp330 obtained by affinitypurification on a column containing RAP (27) .
Anti-LRPla2MR Antibodies. Affinity-purified IgG was prepared from a rabbit anti-human LRPIa2MR antiserum. The antibodies were shown to react with rat LRP/a2MR by Western blotting and ELISA. There was no reactivity against RAP. No crossreactivity with the LDL receptor was detected by Western blotting of human placental extracts (unpublished observations).
Antisera to the a2-macroglobulin Receptor-associated Protein. An antiserum against a rat RAP-glutathione transferase (GST) fusion protein was kindly provided by Joachim Herz (University of Texas, Southwestern Medical Center, Dallas, TX). The antiserum reacts with a protein of about 44 KD in preparations of gp330, using Western blot analysis (23) . We prepared an additional antiserum against the fusion protein (provided by Joachim Herz) (31) by immunizing a New Zealand White rabbit intrader-mally with 50 pg of the fusion protein in complete Freund's adjuvant. The two antisera gave identical results in the immunohistochemical studies described below. Rabbit antibodies to GST (in the form of immunoglobulin purified by protein A chromatography) were obtained from Amrad Corporation (Victoria, Australia). The antibodies react specifically with the GST moiety of fusion proteins expressed in E. coli.
Antibody to Renal H' ATPase. An MAb against the 31 KD subunit of the kidney vacuolar H+ ATPase and an anti-peptide antibody against the kidney isoform of the 56 KD subunit have been described previously (42) (43) (44) .
Construction and Expression of an RAPIg Fusion Protein. A soluble RAPIg fusion protein was constructed by ligating synthetic oligonudeotideprimed, polymerase chain reaction-amplified cDNA sequences specific for human RAP to human genomic IgG Fc immunoglobulin sequences in an Ig expression vector (41, 45) . Oligonucleotide primers were designed to incorporate endonuclease restriction sites (XhoI for the forward primer and BamHI for the reverse primer) to facilitate subsequent in-frame ligation to the Ig expression vector. Oligonucleotide sequences for the forward primer were:
5'-CGC GGG CTC GAG ATG GCG CCG CGG AGG GTC AGG TCG-3' and for the reverse primer:
Incorporated restricted restriction sites are denoted in bold print. The reverse primer was designed to exclude the HNEL sequence at the carboxy terminus of RAP.
Amplified sequences were subjected to XhoIlBamHI endonuclease digestion and ligated to XhoIIBamHI-cut CD5-Ig expression vector.
The RAP-Ig expression vector was introduced into COS cells, and transfected cell supernatants were harvested at 5-7 days. Cells were grown in serum-free media to avoid contamination by serum proteins. RAP-Ig was purified on protein A-uisacryl beads (Pierce; Rockford. IL), eluted with 0.1 M acetic acid, neutralized with 2 M Tris, dialyzed, and the concentration of purified protein determined. Typically, the supernatant contained 1-2 pg/ml of the fusion protein.
Animals. Tissues were obtained from normal male and female Lewis rats, weighing 160-200 g. In addition. specimens ofplacenta were obtained from 18-and 19-day pregnant rats.
Immunofluorescence Methods. For most studies, blocks of organs obtained from rats immediately after sacrifice were embedded in OCT compound (Baxter; Medford, MA), frozen in liquid nitrogen, and stored at -85°C until used. Sections cut at 5 pm were placed on slides, air-dried for 30 min, and then fixed in acetone for 5 min. A section from each block was stained with hematoxylin or toludine blue. In some studies designed to determine the location of RAP, organs were obtained from rats fixed by perfusion with paraformaldehyde-lysine-periodate (PLP) fixative as previously described (21.46). A brief perfusion in situ was followed by excision of tissue blocks and overnight fixation at 4°C. Before cryosectioning, small pieces were rinsed three times in PBS and immersed in 30% sucrose in PBS for at least 1 hr. Sections were incubated with normal goat serum (1:lO) for 20 min and then with 20 pl of primary antibodies for 1 hr. The anti-RAP antisera were used at a dilution of 1:200 and the monoclonal anti-gp330 antibodies and the rabbit anti-human LRPla2MR IgG at concentrations of 20 pg/ml. As controls, sections were incubated with normal rabbit serum or pre-immune serum (in the case of anti-RAP) or with normal mouse IgG, at the same concentrations. After washing, the sections were incubated for 1 hr with 20 p1 of the appropriate secondary antiserum, either FITCconjugated goat anti-rabbit IgG (Cappel; Durham, NC) or FIE-conjugated goat anti-mouse IgG antiserum (Sigma; St Louis, MO), which had been absorbed with normal rat serum.
In some studies of the lung, double staining was performed to determine if there was co-localization of gp330 and LRPla2MR in Type I1 pneumocytes: Frozen sections were incubated with the murine MAb anti-gp330 (14C1) and the rabbit anti-LRP1aZMR antiserum, followed by incubation with FIE-labeled goat anti-rabbit IgG and rhodamine-labeled goat antimouse IgG (Cappel).
To detect binding sites for RAP, two methods were used. In one, sections of PLP-fixed or fresh frozen tissue were incubated for 1 hr with RAPIg and then, after washing, with FITC-conjugated goat anti-human IgG (Cappel) which had been absorbed with normal rat serum. In the second method, sections were incubated with 10 lglml of the RAP-GST fusion protein, followed by rabbit anti-GST antibodies and then FIX-conjugated goat anti-rabbit IgG. The two methods produced identical staining patterns.
Immunoperoxidase Methods. Most organs were also studied by immunoperoxidase methods for the location of gp330, LRPla2MR. and of RAP and its binding sites. Some organs were also stained with murine MAb to monocytelmacrophages, lymphocyte subsets, and Class I1 MHC antigens to help identlfy certain cells that were reactive with antibodies to LRP/a2MR. The following MAb were used: anti-CD3 (W3l13) anti-CD8 (Ox&?), anti-Class I1 (0x3 and 0x6) (all from Acurate; Westbury, NY), and ED1 (from Dr. C. D. Dijkstra), which recognizes rat monocytelmacrophages (47) .
For immunoperoxidase studies, frozen sections were blocked with k100 normal horse serum (Vector; Burlingame, CA) or normal goat serum in avidin solution (Vector) for 30 min. then incubated for 90 min with primary MAb. After blocking with 10 pglml d-biotin (Sigma) in PBS with 0.03% H202 (Fisher; Fair Lawn, NJ) for 30 min. sections were incubated for 35 min with 1:lOO biotin-conjugated horse anti-mouse IgG (Vector) or 1100 biotin-conjugated goat anti-rabbit IgG (Sigma), which had been preabsorbed with normal rat serum, followed by 41-min incubation with avidinbiotin complex (Vector). Development of 3-amino-9-ethylcarbazole (AEC) (Sigma) was monitored under the microscope. Sections were counterstained with hematoxylin (Sigma).
Results
The locations of cells reactive with MAb against a 3 3 0 and with rabbit antibodies against LRP/a2MR and RAP, as well as binding sites for the RAP-Ig or the RAFGST fusion protein, are summarized in Table 1 . Additional information obtained with MAb to CD3, CD8, Class I1 MHC molecules, and monocytelmacrophages (ED1) is described in the text.
Distribution of @330
Gp330 was found in a restricted group of epithelial cells. Selected organs are illustrated (Figures 1 and 4a) , and a few organs with distinctive or previously undescribed findings are commented on below. In nearly all cells, staining was restricted to the apical portion; in some of these cells, notably epididymal epithelium (Figure Id) and renal proximal tubule cells, subapical vesicles containing gp330 were prominent and microvilli were clearly stained. In parathyroid cells, diffuse cell staining was seen ( Figure IC) . In ciliary epithelium of the eye, germinal epithelium of ovary, and ependymal cells, staining was seen mainly at the apical surface but appeared to extend to lateral portions of the cells as well (Figures la and 1b).
In epididymis, gp330 was found on principal cells and was most prominent in the tail and body. Isolated epithelial cells (clear cells) did not stain for gp330 ( Figure Id) ; these cells were shown to be reactive with antibodies against a proton ATPase (42) .
In placenta, staining for gp330 was found in an irregular layer in the labyrinth zone, which appeared to represent a syncytial layer of trophoblasts (Figure 4a ), based on comparison with electron microscopic descriptions of the rat placenta (48) . In addition, very intense apical staining of yolk sac epithelium was seen, including cells of yolk sac villi that invaginated the labyrinth zone.
Distribution of LRPIa2M.R
The distribution of LRP/a2MR differed strikingly from that of gp330. There was widespread staining of LRPla2MR of interstitial cells; in some organs the cells appeared to be mainly fibroblasts, but in other sites, especially in lymph nodes, lamina propria of small intestine, skin, lung, and placenta, many cells with the appearance of macrophages were also reactive. The MAb specific for monocytelmacrophages (ED1) stained many such cells, as seen by examination of contiguous sections of lymph nodes, skin, and placenta. In thymus, lymph nodes, and skin, cells with a dendritic appearance were stained for LRP/a2MR ( Figure 2d ); in the skin, some such cells were shown to be reactive with antibodies to Class I1 MHC antigens, as seen in contiguous sections stained for LRPla2MR and Class I1 MHC molecules. Fibroblasts, macrophages, and dendritic cells exhibited diffuse cytoplasmic staining for LRP/a2MR; surface reactivity could not be evaluated. As far as could be determined, no CD3or CD8-positive cells stained for LRPla2MR.
In lung, many cells in alveolar walls stained for LRP/a2MR, including fibroblasts, macrophages, dendritic cells, and other unidentified septal cells. Because of the many stained cells, it could not be determined if LRP/a2MR was present on Type I1 pneumocytes. However, in sections double stained for LRPla2MR and gp330, Type I1 pneumocytes stained only for gp330.
Certain epithelial cells were also reactive with antibodies to LRPl a2MR, including hepatocytes, adrenal cortical cells, and epithelial cells of the choroid plexus, ciliary body of the eye, cornea, and retinal cells (Figure 2c ). Staining for LRPla2MR was especially intense in cells of the ciliary body and of the choroid plexus, where a diffuse granular cellular pattern was seen (Figures 2a and 2b) . Hepatocytes showed intense staining, mainly on the sinusoidal (basolateral) surface, but also as cytoplasmic vesicles near the cell surface. In the adrenal cortex, cells of the zona glomerulosa stained brightly and those of the zona fasciculata slightly less so; in the latter zone the staining was restricted to one surface of the cell.
In addition, certain specialized cells were reactive with antibodies to LRP/aZMR, including spermatids, follicular cells of ovary, some astrocytes and neurons, mesangial cells, and cells in the labyrinth zone of the placenta, where many round or elongated cells were seen in the fetal mesenchyme (Figure 4b ). In the basal zone of the placenta, groups of round cells were stained; some of these cells were also reactive with ED-1, indicating that they were macrophages, but some of the cells stained for LRP/a2MR may have been trophoblasts.
The only cells that unequivocally stained both for LRP/a2MR and gp330 were epithelial cells of the retina and ciliary body. Moreover, in the ciliary epithelium the pattern of staining for the Most organs contain fibroblasts, macrophages, andlor dendritic cells that stain for LRPlaZMR. Organs without staining of epithelial or special cells for LRP/aZMR or gp330 are not tabulated. The following organs and tissues were examined in addition to those listed: gastrointestinal tract, pancreas, skin, heart, skeletal muscle, pituituy. lymph nodes, spleen, and thymus.
Staining for gp330 was found on apical surfaces, including microvilli and subapical vesicles. In addition, diffuse cell staining was seen in the parathyroid and retinal pigmented layer.
The location of RAP was determined in PLP-fiwed tissue (see text), whereas gp330, LRPlaZMR. and binding sites for soluble RAP were determined in frozen sections. In all cells that stained for RAP, the pattern was intracellular.
In cells with diffuse cell staining, surface stain could not be evaluated. two proteins differed: gp330 was concentrated at the apical surface of cells at the interface between the pigmented and non-pigmented layers ( Figure Ib) , where& LRFVa2hfR was seen throughout both layers of the cells (Figure 2b ). We were unable to exclude the possibility that there was co-localization in certain other cells, i.e., in isolated cells of the breast ducts, in some ependymal cells, and in scattered trophoblasts i n the labyrinth zone of the placenta. In certain organs, staining for LRPIa2MR appeared to be located in the extracellular matrix; however, further studies, especially at the ultrastructural level, will be required to c o d m this.
Distribution of RAP
The location of RAP was determined by use of antibodies to a RAPGST fusion protein. Antibodies to GST did not produce any of the staining pattems described in the present section. RAP was found in all cells that expressed LRp/a2MR or gp330. Thus, there was staining offibroblasts, macrophages, and dendritic cells in many organs, as well as of selected epithelial and special cells (Zble 1).
The precise location of staining for RAP was dependent on the method used to process the tissue. As we described in a previous study, which dealt with the kidney (41), RAP was found almost exclusively in intracellular vesicles in PLP-f=ed tissue but was seen only on brush borders in sections prepared from fresh frozen kidney. We showed that during processing of frozen sections, RAP was artifactually released from intracellular vesicles and then bound to gp330 on brush borders. The intravesicle sites (shown by electron microscopy to be mainly rough endoplasmic reticulum) revealed in PLP-fixed tissue appeared to reflect the normal location of RAP.
In the present study, certain epithelial cells in organs other than the kidney also exhibited intracellular staining for RAP in PLPfixed tissue but lacked such staining in frozen sections. This difference was clearly seen in cells where LRP/a2MR or gp330 was concentrated near or on the cell surface, such as epididymis, thyroid, and hepatocytes. In contrast, in cells with diffuse cell staining for LRPl a2hfR (e.g., fibroblasts, macrophages, choroid plexus) (Figure 3a) . and epithelium of the ciliary body (Figure 3 b) or for gp330 (parathytoid), intracellular RAP was found both in fresh frozen and PLP fixed tissue. Clear-cut cell surface staining for RAP was not found in PLP-fixed tissue.
Dihibution of RAP binding Sites
The location of binding sites for RAP, detected by incubation of sections with the soluble RAP-human Ig fusion protein or the GST-RAP fusion protein, was the same in sections of frozen or PLPfixed tissue. Binding was observed only to cells that expressed either LRP/a2MR or gp330 and in pattems that were similar to the location of these two proteins. There was staining of the surface of renal proximal tubules and epididymal, hepatic (Figure 3d) , and adrenal cells. In renal proximal tubules and epididymal cells, there was clear-cut staining of microvillar regions. In addition, there was diffuse cellular staining of fibroblasts, macrophages, epithelium of the ciliary body, choroid plexus (Figure 3c ), and parathyroid.
Discussion
In the present immunohistochemical study we have extended observations on the distribution of gp330 and LRPIa2MR in rat organs and have provided new information about the location of RAP and the sites to which exogenous soluble RAP binds.
In confirmation of previous reports, we found gp330 on a restricted group of epithelial cells, as summarized in Eble 1. Our findings on the distribution of gp330 agree closely with those of Assmann et al. (33) , who performed an extensive survey of rat organs for gp330 (and a 90 KD glycoprotein later identified as dipeptyl peptidase IV), and of Chatelet et al. (35) , who performed a more limited survey. In contrast with our study and that of Chatelet, in which MAb were used, Assmann et al. employed antibodies eluted from the glomeruli of rats that had been injected with an antiserum against mouse renal tubule antigens. They provided evidence that the antibodies were specific for gp330 by showing that the eluates precipitated from renal brush-border preparations a single protein that also reacted with an MAb to gp330.
In most cells, gp330 was found in the apical portion, and in certain cells was seen in subapical vesicles. In some cells staining was clearly on the cell surface, including brush borders. On the basis of ultrastructutal studies, different conclusions have been reached conceming the precise location of gp330 on the surface of cells with microvilli. Kerjaschki et al. (49) have concluded that gp330 in renal proximal tubule cells is restricted to the base of the microvilli, in the region of coated pits (the intermicrovillar microdomain), and although they observed reactivity over the surface of microvilli with a polyclonal anti-gp330 antiserum, they attributed this to crossreactivity with maltase. However, we (20,21) and others (34) have shown that gp330 can be detected by several MAb on the entire surface of microvilli, especially in certain segments of the proximal tubules. It is unlikely that all of the MAb crossreact with maltase, especially since some of them have been shown not to react with small intestinal epithelium (35) , where maltase is abundant. In addition, we have shown that exogenous soluble RAP-Ig binds to the entire surface of microvilli in some proximal tubules when applied to sections of renal tissue (41). Since renal tubule cells do not express LRFVa2A4R or the LDL receptor (the only other receptors known to bind RAP), this finding provides strong evidence that gp330 is indeed located on microvilli.
In the present study gp330 was present both in coated pit regions and on microvilli (sterocilia) of epididymal cells. In contrast, Chatelet et al. (35) reported that gp330 was restricted to coated pit and api- cal vesicles in these cells. In the same study, they found gp330 over the entire surface of microvilli of Type I1 pneumocytes.
Therefore, it appears that although gp330 is concentrated in coated pit regions in some epithelial cells, in others it is also present over microvilli. In a recent study, we obtained evidence that gp330 on the surface of the microvilli of renal tubules may have a different primary structure from that present in coated pit regions (50) . We found that an antiserum against a cytoplasmic peptide of gp330 produced staining in the coated pit regions but not over microvilli of proximal tubules, suggesting that the gp330 over microvilli either lacks or has a modified cytoplasmic domain.
Another point of interest concerns the apparent abundance of intracellular gp330 in parathyroid cells. As in previous studies, we observed little intracellular staining for gp330 in most cells, except for subapical vesicles. Furthermore, although some ultrastructural studies have revealed gp330 in the rough endoplasmic reticulum, in other studies gp330 has not been detected in appreciable amounts in this location (20, 37) . Like gp330, LRPla2MR was found on a selected group of epithelial cells. However, almost all of the cells were different from those that expressed gp330: the only cells that clearly stained for both proteins were epithelial cells of retina and ciliary body of the eye. In addition, LRPla2MR was found in interstitial cells in virtually all organs, i.e., in fibroblasts, monocytelmacrophages. and dendritic cells (in the skin and lymphoid tissue). LRPla2MR was also present in glomerular mesangial cells, neurons, spermatids, and follicular cells of ovary.
Because we used polyclonal antibodies to detect LRPIa2MR. the possibility must be considered that some of the staining may have resulted from crossreacting epitopes on other proteins, notably gp330, RAP, or the LDL receptor. However, by Western blotting and ELISA no reactivity of the anti-LRPla2MR antibodies with these proteins was found (unpublished observations). Furthermore, the anti-LRPla2MR antibodies did not react with gp330 or RAP in tissue sections, as shown by their failure to stain brush borders of renal tubules in frozen sections, where these proteins are abundant.
Our findings of the distribution of LRPIa2MR in the rat are similar to those described in a recent study of human tissues by Moestrup et al. (18) . However, we did not find staining of "columnar epithelial cells of the gastrointestinal tract:' as described by these authors. In addition, we found staining of choroid plexus cells, which was not described by Moestrup nor in a separate study of the human brain (51) . It is not clear whether the discrepancies result from variation among species or differences in methodology.
In most epithelial cells where we detected LRPla2MR. it was concentrated near or on the cell surface, in keeping with its role as a receptor. The receptor function of LRPla2MR in vivo has been investigated mainly by determining clearance of circulating ligands, including protease-a2M complexes or ApoE-enriched VLDL (14). Such studies have shown that endocytosis takes place mainly in hepatic cells (17). However, other cells may contribute to the removal of circulating ligands, including Kupffer cells and mesangial cells, although probably only to a minor extent. It is known that circulating immune complexes can accumulate in mesangial regions, often with damaging effects (52) .
Interstitial cells that express LRPla2MR would not normally be expected to mediate removal of circulating ligands, but at sites of inflammation might endocytose extravasated or locally released products, such as cytokines bound to a2-macroglobulin (53), protease-anti-protease complexes, or other ligands that bind to a2macroglobulin. Willnow et al. (16) recently reported that gp330 and LRP both bind several of the same ligands, including tPAIPAI-1 complexes, ApoE-enriched/ PVLDL complexes, lipoprotein lipase, and lactoferrin. Nevertheless, as noted by these authors, because of striking differences in distribution, the two receptors probably are involved in endocytosis of different ligands. In particular, since gp330 is not found on the surface of cells that face the circulation (with the apparent exception of parathyroid cells), it would not be expected to endocytose circulating ligands, but rather components of the fluids to which it is exposed.
Furthermore, in certain cells, LRPIaZMR and LRP may perform functions other than endocytosis. The intense staining of the choroid plexus for LRP/a2MR and for both LRPIa2MR and gp330 in the ciliary body, cells that are involved in the formation of cerebral spinal fluid and aqueous humor, suggests a role of these proteins in transport or secretion. In this regard, it is of interest that known ligands of LRPla2MR and gp330-ApoE and ApoAl-are constituents of CSF (54, 55) .
In the present study, major new information was obtained about the tissue distribution of RAP and its binding sites, which were detected by a soluble RAP-Ig or -GST fusion protein. Soluble RAP bound to all cells that expressed gp330 or LRP/a2MR, and only to such cells. Therefore, we failed to find evidence of proteins other than gp330 and LRP/a2MR to which the RAP binds; however, the methods used do not permit exclusion of this possibility.
The binding sites detected by the soluble RAP were clearly on the surface of cells that expressed cell surface gp330 or LRP/a2MR, notably on hepatic, adrenal, and ovarian follicular cells, epididymis, and renal proximal tubules. This finding provides evidence of the availability of surface receptor-binding sites on these cells. In other cells in which diffuse intracellular LRPIa2MR or gp330 was seen, notably fibroblasts, macrophages, ciliary epithelium, choroid plexus, and parathyroid, similar diffuse binding of soluble RAP was seen. It was not possible to determine if there was also binding to the cell surface in these cells.
The location of RAP in cells, as detected by antibodies to a RAP-GST fusion protein, clearly differed from its binding sites in many cells. Wherever it was found, RAP was almost entirely within cells, whereas, as just noted, exogenous soluble RAP bound exclusively to the surface of those cells with surface gp330 or LRP/ a2MR. A critical aspect in determining the location of endogenous RAP is the method used to process the tissue, as we showed in a previous study of renal tissue (41) . In sections of fresh frozen tissue, whether subsequently fixed in acetone or unfixed, RAP in proximal tubules was found almost entirely on brush-border regions, as also described by Orlando et al. (23) . In contrast, in PLP-fixed tissue RAP was almost entirely within intracytoplasmic vesicles. We obtained evidence that the brush-border staining seen in frozen sections resulted from release of soluble RAP from intracellular sites, with subsequent binding to gp330 on the brush border. By electron microscopic study of PLP-fixed renal tissue, RAP was found almost entirely in the rough endoplasmic reticulum, which appears to be its true location.
In the present study we found loss of intracellular RAP from certain extrarenal cells in frozen sections, by comparison with PLPfixed tissue. In particular, this was found in cells that expressed gp330 or LRPlaZMR principally on or near the cell surface. In contrast, in cells with diffuse intracellular LRP/RAP or gp330, RAP was not released from intracellular sites even in frozen sections (Figures 3a and 3b ), possibly because it is tightly bound to the receptors.
We did not find clear-cut evidence of cell surface staining for RAP in PLFfixed tissue. The finding that soluble RAP fusion proteins bound to surface gp330 or LRP/a2MR in tissue sections (whether fresh frozen or PLP fixed) renders unlikely the possibility that our failure to detect endogenous RAP on cell surfaces was due to technical factors, e.g., loss of surface RAP during processing or loss of antigenic reactivity due to fixation. The lack or paucity of RAP on cell surfaces obviously has implications concerning its function. In vitro, RAP has been shown to inhibit binding of ligands to gp330 and to LRP/a2MR (16, 30) , and to bind to gp330 on renal proximal tubule cells (22, 41) . Nevertheless, $RAP does not normally gain access to these receptors on the cell surface, it may not be able to modulate their function in vivo. Its main function, therefore, may be an intracellular one, possibly involving transport and/or processing. However, it is likely that immunocytochemical methods are inadequate to detect small amounts of surface RAP. Indeed, studies employing surface iodination of cultured fibroblasts and monocytes have provided evidence that small amounts of RAP are on the cell surface (23, 56) , and in our earlier study electron microscopy revealed evidence of RAP in a few clathrin-coated pits at the base of microvilli in some renal proximal tubule cells (41) . Further studies are needed to determine the extent to which RAP is normally present on cell surfaces and to assess the possibility that RAP functions to inhibit ligand binding in vivo.
